FeesSafety
Pluang+

EU approves Sanofi's new-generation rabies vaccine VaxRabeo for all ages

Market News
19 Nov 2026, 13:00 WIB
Sanofi
View Source
Bullish
EU approves Sanofi's new-generation rabies vaccine VaxRabeo for all ages

Sanofi's new rabies vaccine, VaxRabeo, has been approved by the European Commission for use in all age groups for both pre-exposure and post-exposure prophylaxis. The vaccine, made with advanced Vero cell technology, offers longer shelf life and better stability than existing vaccines. Rabies remains a deadly disease with no cure once symptoms appear, making vaccination critical. This approval follows positive clinical trial results showing VaxRabeo's safety and effectiveness comparable to current Sanofi vaccines, supporting global efforts to prevent rabies deaths.

Sanofi's stock is trading at USD 47.01 on Pluang, down 1.09% as of Nov 19, 2026 13:01 WIB. The company holds a market cap of $114.30 billion and offers a dividend yield of 5.09%.

More News (SNY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App